Q-omics provides the consensus-scored ZNF552 profile across patient tissues and cancer cell-line models. ZNF552 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, ZNF552 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, ZNF552 RNA expression shows 20,822 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight COAD, KIRC, and UVM as cancer lineages where ZNF552 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF552 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF552 survival associations across molecular data types. ZNF552 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF552 RNA expression–survival associations across cancer types. High ZNF552 expression shows unfavorable associations in ACC and LGG, but favorable associations in COAD, BRCA, KIRC and HNSC. The COAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for ZNF552 RNA expression.
This table summarizes ZNF552 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF552. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF552 shows lower tumor expression in KIRC, KIRP and KICH and higher tumor expression in LIHC, BRCA and UCEC. The KIRC box plot shows higher ZNF552 RNA expression in normal versus tumor tissue (log2 FC = −0.903, t-test p < 0.001).
This table shows molecular features associated with ZNF552 in patient tissues and cancer cell lines. In patient samples, ZNF552 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF552 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BREAST.
